Advanced cervix cancer patient with chemotherapy-induced grade IV myelosuppression achieved complete remission with cadonilimab:A case report  

作　　者：Rui Zhu Tian-Ze Chen Meng-Ting Sun Chun-Rong Zhu 

机构地区：[1]Department of Oncology,The First Affiliated Hospital of Soochow University,Suzhou 215000,Jiangsu Province,China [2]Department of Urology,The First Affiliated Hospital of Soochow University,Suzhou 215000,Jiangsu Province,China

出　　处：《World Journal of Clinical Cases》2024年第8期1510-1516,共7页世界临床病例杂志

摘　　要：BACKGROUND The prognosis for patients with advanced metastatic cervix cancer(MCC)is poor,and this disease continues to pose a considerable therapeutic challenge.Despite the administration of first-line regimens consisting of cisplatin,paclitaxel,and bevacizumab,survival rates for patients with metastasis remain poor.The emergence of bispecific antibodies(BsAbs)offers a novel treatment option for patients diagnosed with MCC.CASE SUMMARY In this report,we present a patient with MCC who was treated with cadonilimab monotherapy at a dose of 6 mg/kg every two weeks after chemotherapy was proven to be intolerable.The patient exhibited a sustained complete response for a duration of 6 months,demonstrating an optimistic outlook.CONCLUSION This case illustrates the considerable efficacy of cadonilimab for treating advanced MCC.Therefore,BsAb therapy is a promising strategy for effectively treating patients with advanced MCC and should be considered as an option when patients are intolerant to standard chemotherapy.

关 键 词：Cadonilimab Complete response Bispecific antibodies Recurrent or metastatic cervical cancer Programmed death protein 1 Cytotoxic T-lymphocyteassociated antigen-4 Case report 

分 类 号：R734.2[医药卫生—肿瘤]